Investigation of expression and influence of CTGF and HO-1 in rats with diabetic retinopathy

Huang,Yongjian; Qian,Chaoxu; Zhou,Jilin; Xue,Jinsong

doi:10.3892/etm.2019.8395

Investigation of expression and influence of CTGF and HO-1 in rats with diabetic retinopathy

Authors:
- Yongjian Huang
- Chaoxu Qian
- Jilin Zhou
- Jinsong Xue
View Affiliations

Affiliations: Department of Ophthalmology, The Third People's Hospital of Changzhou, Changzhou, Jiangsu 231001, P.R. China, Department of Ophthalmology, Nanjing Medical University Affiliated Eye Hospital, Nanjing, Jiangsu 210029, P.R. China
Published online on: December 30, 2019 https://doi.org/10.3892/etm.2019.8395
Pages: 2291-2295

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression and influence mechanism of CTGF and HO-1 in rats with diabetic retinopathy (DR) was investigated. One hundred and thirty male Sprague‑Dawley (SD) rats were selected and randomly divided into the control group and DR group, with 65 rats in each group. DR was caused by intraperitoneal injection of streptozotocin in rats in the DR group. There were 55 successful models and 10 failed in the modelling. The successful models were sacrificed at the 2nd, 4th and 6th month, respectively. RT-qPCR technology was used for detection of the expression of CTGF and HO-1 in rat retina in each group, H&E staining for observation of the gradation structure in rat retina and TUNEL method for detection of apoptosis of retinal cells. In the DR group, the retina layers were disordered and a few blood vessels dilated at the 2nd month. In the DR group, the inner membrane of the retina swelled, and the ganglion cells were irregularly arranged at the 4th month. In the DR group, dilatation of the blood vessels was more obvious, the inner membrane edema was more severe, and the arrangement was more irregular at the 6th month. The retinal apoptosis rate of DR rats gradually increased at the 2nd, 4th and 6th month, after which, the CTGF expression gradually increased, but the HO-1 expression gradually decreased in retina in the DR group. However, the mRNA expression of CTGF and HO-1 in the rats at the 2nd, 4th and 6th month in the DR group was higher than that in the control group at the same period. Therefore, CTGF and HO-1 are associated with the occurrence and development of DR in rats and can be considered as targets for the treatment of DR.

View Figures

View References

1	Pedersen BK: Anti-inflammatory effects of exercise: Role in diabetes and cardiovascular disease. Eur J Clin Invest. 47:600–611. 2017. View Article : Google Scholar : PubMed/NCBI
2	Welborn TA, Garcia-Webb P, Bonser A, McCann V and Constable I: Clinical criteria that reflect C-peptide status in idiopathic diabetes. Diabetes Care. 6:315–316. 1983. View Article : Google Scholar : PubMed/NCBI
3	Song Y, Huang L and Yu J: Effects of blueberry anthocyanins on retinal oxidative stress and inflammation in diabetes through Nrf2/HO-1 signaling. J Neuroimmunol. 301:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
4	NCD Risk Factor Collaboration (NCD-RisC): Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 387:1513–1530. 2016. View Article : Google Scholar : PubMed/NCBI
5	Liu Q, Zhang F, Zhang X, Cheng R, Ma JX, Yi J and Li J: Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. Mol Cell Biochem. Dec 21–2017.(Epub ahead of print).
6	Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al FIELD study investigators, : Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet. 370:1687–1697. 2007. View Article : Google Scholar : PubMed/NCBI
7	Henshaw FR, Boughton P, Lo L, McLennan SV and Twigg SM: Topically applied connective tissue growth factor/CCN2 improves diabetic preclinical cutaneous wound healing: Potential role for CTGF in human diabetic foot ulcer healing. J Diabetes Res. 2015:2362382015. View Article : Google Scholar : PubMed/NCBI
8	Liu F, Tang W, Chen D, Li M, Gao Y, Zheng H and Chen S: Expression of TGF-β1 and CTGF is associated with fibrosis of denervated sternocleidomastoid muscles in mice. Tohoku J Exp Med. 238:49–56. 2016. View Article : Google Scholar : PubMed/NCBI
9	Montford JR and Furgeson SB: A new CTGF target in renal fibrosis. Kidney Int. 92:784–786. 2017. View Article : Google Scholar : PubMed/NCBI
10	Klaassen I, van Geest RJ, Kuiper EJ, van Noorden CJ and Schlingemann RO: The role of CTGF in diabetic retinopathy. Exp Eye Res. 133:37–48. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhang H, Cai X, Yi B, Huang J, Wang J and Sun J: Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy. Mol Med Rep. 9:2138–2144. 2014. View Article : Google Scholar : PubMed/NCBI
12	Liu J, Wang L, Tian XY, Liu L, Wong WT, Zhang Y, Han QB, Ho HM, Wang N, Wong SL, et al: Unconjugated bilirubin mediates heme oxygenase-1-induced vascular benefits in diabetic mice. Diabetes. 64:1564–1575. 2015. View Article : Google Scholar : PubMed/NCBI
13	Chen YC, Chen BC, Yu CC, Lin SH and Lin CH: miR-19a, −19b, and −26b mediate CTGF expression and pulmonary fibroblast differentiation. J Cell Physiol. 231:2236–2248. 2016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Zinman B, Lachin JM and Inzucchi SE: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 374:10942016.PubMed/NCBI
16	Pothineni NV and Mehta JL: Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 373:977–978. 2015. View Article : Google Scholar : PubMed/NCBI
17	Piette JD, Heisler M and Wagner TH: Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 27:384–391. 2004. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Duan L, Guo T, Gao Y, Tian L, Liu J, Wang S and Yang J: Downregulation of miR-30c promotes renal fibrosis by target CTGF in diabetic nephropathy. J Diabetes Complications. 30:406–414. 2016. View Article : Google Scholar : PubMed/NCBI
19	Zhu L, Zhao S, Liu S, Liu Q, Li F and Hao J: PTEN regulates renal extracellular matrix deposit via increased CTGF in diabetes mellitus. J Cell Biochem. 117:1187–1198. 2016. View Article : Google Scholar : PubMed/NCBI
20	Negi G, Nakkina V, Kamble P and Sharma SS: Heme oxygenase-1, a novel target for the treatment of diabetic complications: Focus on diabetic peripheral neuropathy. Pharmacol Res. 102:158–167. 2015. View Article : Google Scholar : PubMed/NCBI
21	Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van der Woude FJ, Waldherr R, Rabelink TJ, de Heer E, et al: Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 71:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
22	Sun J, Zheng H, Qin X and Qi L: Effects of immunocytokine combined with cattle encephalon glycoside and ignotin on CTGF, HO-1 and NT-3 in patients with type 2 diabetic peripheral neuropathy. Iran J Public Health. 46:1632–1638. 2017.PubMed/NCBI